The planned purchase will make Brocacef a leading service provider in the Dutch healthcare market. With a total of 5,300 employees and revenue of EUR 2.1 billion, Brocacef continues to expand its range, and by acquiring the pre-wholesale activities, it will be able to offer more comprehensive services along the pharmaceutical supply chain in the future. Customers such as the pharmaceutical industry, pharmacies, hospitals, patients as well as health insurance companies, will benefit because Brocacef can offer an even broader range of services, thereby becoming an even more attractive partner in all areas. With the intended acquisition, Brocacef is ensuring that professional healthcare in the Netherlands remains not only easily accessible, but also affordable.
Oliver Windholz, CEO of the PHOENIX group, said: “The planned acquisition will strengthen the market position of the PHOENIX group as integrated healthcare provider in Europe in the long term. The activities of Brocacef and Mediq complement each other perfectly – due to the geographical set-up as well as their portfolios. With the targeted acquisition we will achieve an optimal positioning in the Netherlands as the link between manufacturer and patient.”
Consultation with the works councils of both companies is already in progress. The relevant trade union representatives have already been informed about the planned acquisition.
It has been agreed that financial details of the transaction will not be disclosed.